E
SPRB

Ergoteles’s Spruce Biosciences SPRB Stock Holding History

Ergoteles’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-307
Closed -$32K – 1966
2022
Q3 		$32K Sell
307
-252
-45% -$35.2K ﹤0.01% 1462
2022
Q2 		$73K Buy
+559
New +$71.6K ﹤0.01% 1543

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Ergoteles's SPRB Position: Q4 2022 in Review

Ergoteles sold out of Spruce Biosciences (SPRB) in Q4 2022, closing a stake of 307 shares — an estimated $32K sold.

Ergoteles first reported a position in SPRB in Q2 2022 and held it in 2 quarters. The position peaked at $73K in Q2 2022. 29 funds tracked by Wall St. Rank hold SPRB as of Q4 2022.

  • Ergoteles reported no remaining Spruce Biosciences position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 307 Spruce Biosciences shares in Q4 2022, an estimated $32K.
  • Ergoteles first reported a position in Spruce Biosciences in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Spruce Biosciences position peaked at $73K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.